SynthesisAnnals of oncology : official journal of the European Society for Medical Oncology2022
Deciphering radiological stable disease to immune checkpoint inhibitors.
Synthesis in Annals of oncology : official journal of the European Society for Medical Oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06004713 (Multi-center, Non-interventional, Prospective Registry Study on the Treatment of Solid Tumors With Mismatch Repair Deficiency or Microsatellite Instability), which is not on this map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Multi-center, Non-interventional, Prospective Registry Study on the Treatment of Solid Tumors With Mismatch Repair Deficiency or Microsatellite Instability
Who cites it
31 citing papers in PubMed, 47 citations in OpenAlex.
- Consolidative stereotactic radiotherapy for oligo-residual non-small cell lung cancer after first-line chemoimmunotherapy: A single-arm, phase 2 trial from China.PLoS medicine · 2025Trial
- Early Immune Remodeling Steers Clinical Response to First-Line Chemoimmunotherapy in Advanced Gastric Cancer.Cancer discovery · 2024Trial
- Beyond cold to hot: oncolytic virotherapy as the next cornerstone of immuno-oncology.Nature reviews. Clinical oncology · 2026Review
- Optimizing neoadjuvant chemoimmunotherapy cycles based on radiologic response improves efficacy and survival in non-small cell lung cancer.Translational lung cancer research · 2026Article
- Dual-time-point [EJNMMI research · 2026Article
- Inflammatory biomarkers refine progression risk stratification in NSCLC patients with stable disease.Translational oncology · 2026Article
- Article
- From Radiomics to Radiogenomics: Decoding Renal Cell Carcinoma Biology for Precision Medicine-a narrative review.Insights into imaging · 2025Review
- Radiomic biomarkers associated with immune checkpoint blockade response for advanced renal cell carcinoma.Urologic oncology · 2025Article
- Long-term clinical outcome of patients with metastatic melanoma and initial stable disease during anti-PD-1 checkpoint inhibitor immunotherapy with pembrolizumab.British journal of cancer · 2025Article
- Dual-energy CT iodine concentration as a biomarker for immunotherapy treatment response in metastatic melanoma and renal cell carcinoma patients.European radiology · 2025Article
- Spatially resolved C1QCCell discovery · 2025Article
- Factors Associated with Disease Progression after Discontinuation of Immune Checkpoint Inhibitors for Immune-Related Toxicity in Patients with Advanced Non-Small Cell Lung Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Article
- CD24, NFIL3, FN1, and KLRK1 signature predicts melanoma immunotherapy response and survival.Journal of molecular medicine (Berlin, Germany) · 2025Article
- NeoPred: dual-phase CT AI forecasts pathologic response to neoadjuvant chemo-immunotherapy in NSCLC.Journal for immunotherapy of cancer · 2025Article
- The baseline circulating immunophenotype characteristics associate with PD(L)-1 targeted treatment response, irae onset, and prognosis.Scientific reports · 2025Article
- Prediction of checkpoint inhibitor immunotherapy efficacy for cancer using routine blood tests and clinical data.Nature medicine · 2025Article
- Dissection of Progressive Disease Patterns for a Modified Classification for Immunotherapy.JAMA oncology · 2025Article
- Quality-of-life scale machine learning approach to predict immunotherapy response in patients with advanced non-small cell lung cancer.Frontiers in immunology · 2025Article
- Advances in Multimodal Imaging Techniques for Evaluating and Predicting the Efficacy of Immunotherapy for NSCLC.Cancer management and research · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 2 institutions in 1 country.
Funding
Abstract
background'Stable disease (SD)' as per RECIST is a common but ambiguous outcome in patients receiving immune checkpoint inhibitors (ICIs). This study aimed to characterize SD and identify the subset of patients with SD who are benefiting from treatment. Understanding SD would facilitate drug development and improve precision in correlative research. PATIENTS AND
methodsA systematic review was carried out to characterize SD in ICI trials. SD and objective response were compared to proliferation index using The Cancer Genome Atlas gene expression data. To identify a subgroup of SD with outcomes mirroring responders, we examined a discovery cohort of non-small-cell lung cancer (NSCLC). Serial cutpoints of two variables, % best overall response and progression-free survival (PFS), were tested to define a subgroup of patients with SD with similar survival as responders. Results were then tested in external validation cohorts.
resultsAmong trials of ICIs (59 studies, 14 280 patients), SD ranged from 16% to 42% in different tumor types and was associated with disease-specific proliferation index (ρ = -0.75, P = 0.03), a proxy of tumor kinetics, rather than relative response to ICIs. In a discovery cohort of NSCLC [1220 patients, 313 (26%) with SD to ICIs], PFS ranged widely in SD (0.2-49 months, median 4.9 months). The subset with PFS >6 months and no tumor growth mirrored partial response (PR) minor (overall survival hazard ratio 1.0) and was proposed as the definition of SD responder. This definition was confirmed in two validation cohorts from trials of NSCLC treated with durvalumab and found to apply in tumor types treated with immunotherapy in which depth and duration of benefit were correlated.
conclusionsRECIST-defined SD to immunotherapy is common, heterogeneous, and may largely reflect tumor growth rate rather than ICI response. In patients with NSCLC and SD to ICIs, PFS >6 months and no tumor growth may be considered 'SD responders'. This definition may improve the efficiency of and insight derivable from clinical and translational research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.